Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,068 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Blueprint of human thymopoiesis reveals molecular mechanisms of stage-specific TCR enhancer activation.
Cieslak A, Charbonnier G, Tesio M, Mathieu EL, Belhocine M, Touzart A, Smith C, Hypolite G, Andrieu GP, Martens JHA, Janssen-Megens E, Gut M, Gut I, Boissel N, Petit A, Puthier D, Macintyre E, Stunnenberg HG, Spicuglia S, Asnafi V. Cieslak A, et al. J Exp Med. 2020 Sep 7;217(9):e20192360. doi: 10.1084/jem.20192360. J Exp Med. 2020. PMID: 32667968 Free PMC article.
Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup.
Touzart A, Mayakonda A, Smith C, Hey J, Toth R, Cieslak A, Andrieu GP, Tran Quang C, Latiri M, Ghysdael J, Spicuglia S, Dombret H, Ifrah N, Macintyre E, Lutsik P, Boissel N, Plass C, Asnafi V. Touzart A, et al. Sci Transl Med. 2021 May 26;13(595):eabc4834. doi: 10.1126/scitranslmed.abc4834. Sci Transl Med. 2021. PMID: 34039737 Free article. Clinical Trial.
PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL.
Andrieu GP, Kohn M, Simonin M, Smith CL, Cieslak A, Dourthe MÉ, Charbonnier G, Graux C, Huguet F, Lhéritier V, Dombret H, Spicuglia S, Rousselot P, Boissel N, Asnafi V. Andrieu GP, et al. Among authors: smith cl. Blood. 2021 Nov 11;138(19):1855-1869. doi: 10.1182/blood.2020010081. Blood. 2021. PMID: 34125178 Free PMC article. Clinical Trial.
Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
Smith C, Touzart A, Simonin M, Tran-Quang C, Hypolite G, Latiri M, Andrieu GP, Balducci E, Dourthe MÉ, Goyal A, Huguet F, Petit A, Ifrah N, Baruchel A, Dombret H, Macintyre E, Plass C, Ghysdael J, Boissel N, Asnafi V. Smith C, et al. Mol Cancer. 2023 Jan 18;22(1):12. doi: 10.1186/s12943-022-01701-x. Mol Cancer. 2023. PMID: 36650499 Free PMC article.
PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.
Pinton A, Courtois L, Doublet C, Cabannes-Hamy A, Andrieu G, Smith C, Balducci E, Cieslak A, Touzart A, Simonin M, Lhéritier V, Huguet F, Balsat M, Dombret H, Rousselot P, Spicuglia S, Macintyre E, Boissel N, Asnafi V. Pinton A, et al. Clin Cancer Res. 2024 Jan 5;30(1):94-105. doi: 10.1158/1078-0432.CCR-23-2159. Clin Cancer Res. 2024. PMID: 37889114
Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts Outcome in T-ALL.
Touzart A, Lengliné E, Latiri M, Belhocine M, Smith C, Thomas X, Spicuglia S, Puthier D, Pflumio F, Leguay T, Graux C, Chalandon Y, Huguet F, Leprêtre S, Ifrah N, Dombret H, Macintyre E, Hunault M, Boissel N, Asnafi V. Touzart A, et al. Clin Cancer Res. 2019 Apr 15;25(8):2483-2493. doi: 10.1158/1078-0432.CCR-18-1844. Epub 2019 Jan 18. Clin Cancer Res. 2019. PMID: 30659025
TREC mediated oncogenesis in human immature T lymphoid malignancies preferentially involves ZFP36L2.
Balducci E, Steimlé T, Smith C, Villarese P, Feroul M, Payet-Bornet D, Kaltenbach S, Couronné L, Lhermitte L, Touzart A, Dourthe ME, Simonin M, Baruchel A, Dombret H, Ifrah N, Boissel N, Nadel B, Macintyre E, Cieslak A, Asnafi V. Balducci E, et al. Mol Cancer. 2023 Jul 10;22(1):108. doi: 10.1186/s12943-023-01794-y. Mol Cancer. 2023. PMID: 37430263 Free PMC article.
1,068 results